Transactions
15
Insider / Moderna, Inc.
Bancel Stephane
Chief Executive Officer at Moderna, Inc.
- Company
- Moderna, Inc.
- Ticker
- MRNA
- First filing on record
- December 15, 2025
- Latest trade on record
- August 6, 2026
- SEC filings
- EDGAR ↗
Bancel Stephane, Chief Executive Officer at Moderna, Inc., has disclosed 15 transactions in MRNA since December 15, 2025: 0 purchases (0 open-market buys) and 5 sales, worth about $50.8M at the reported prices. The latest was filed August 7, 2026, 1 day after the trade.
Open-market buys
0
Sales
5
Avg. disclosure lag
2.1d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Bancel Stephane made no purchases and 5 sales worth $29M, plus 10 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Bancel Stephane has traded 1 stock on record; the largest by dollars is MRNA.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 4 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 8 | 2,879,576 | $21.9M |
| S | Open-market sale | 4 | 499,246 | $28.7M |
| A | Grant or award | 2 | 262,203 | — |
| F | Shares withheld for tax | 1 | 5,450 | $229K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 13 | 0 | 5 · $28.9M |
| 2025 | 2 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | Option / conversion M | August 6, 2026 | August 7, 2026 | 1d | 64,928 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Option / conversion M | August 6, 2026 | August 7, 2026 | 1d | 187,541 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Option / conversion M | August 5, 2026 | August 7, 2026 | 2d | 128,393 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Option / conversion M | August 5, 2026 | August 7, 2026 | 2d | 370,853 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| MRNA | Option / conversion M | August 6, 2026 | August 7, 2026 | 1d | 252,469 | $19 | $4.8M | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Sell S | August 5, 2026 | August 7, 2026 | 2d | 187,044 | $59 | $11.0M | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Sell S | August 5, 2026 | August 7, 2026 | 2d | 39,891 | $58 | $2.3M | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Sell S | August 5, 2026 | August 7, 2026 | 2d | 124,838 | $57 | $7.1M | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Sell S | August 5, 2026 | August 7, 2026 | 2d | 147,473 | $56 | $8.3M | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Option / conversion M | August 5, 2026 | August 7, 2026 | 2d | 499,246 | $19 | $9.6M | 10b5-1 plan | Form 4 ↗ | |
| MRNA | Other A | March 1, 2026 | March 3, 2026 | 2d | 250,932 | — | — | derivative | Form 4 ↗ | |
| MRNA | Sell F | February 11, 2026 | February 13, 2026 | 2d | 5,450 | $42 | $229K | Form 4 ↗ | ||
| MRNA | Other A | February 11, 2026 | February 13, 2026 | 2d | 11,271 | — | — | Form 4 ↗ | ||
| MRNA | Option / conversion M | December 11, 2025 | December 15, 2025 | 4d | 688,073 | — | — | derivative | Form 4 ↗ | |
| MRNA | Option / conversion M | December 11, 2025 | December 15, 2025 | 4d | 688,073 | $11 | $7.5M | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 7, 2026 | Form 4 | 0001682852-26-000153 | 10 | published | EDGAR ↗ |
| March 3, 2026 | Form 4 | 0001682852-26-000044 | 1 | published | EDGAR ↗ |
| February 13, 2026 | Form 4 | 0001682852-26-000017 | 2 | published | EDGAR ↗ |
| December 15, 2025 | Form 4 | 0001682852-25-000094 | 2 | published | EDGAR ↗ |
Other insiders at Moderna, Inc.
- Hoge Stephen President 76 rows
- Mock James M Chief Financial Officer 68 rows
- Klinger Shannon Thyme Chief Legal Officer 64 rows
- AFEYAN NOUBAR Director 7 rows
- Hussain Abbas Director 7 rows
- Horning Sandra Director 6 rows
- McDonnell Michael R. Director 6 rows
- NABEL ELIZABETH G Director 5 rows
- Nader Francois Director 4 rows
- Rubenstein David M. Director 4 rows
Everyone on file, with contracts and lobbying under the company's name: Moderna, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 4 | 15 | December 15, 2025 | August 7, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.